As of Thursday close, X4 Pharmaceuticals Inc.’s (NASDAQ:XFOR) stock was up $0.02, moving up 1.94 percent to $1.05. The average number of shares traded per day over the past five days has been 1,526,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.1600 fall in that time frame. In the last twenty days, the average volume was 1,267,210, while in the previous 50 days, it was 2,284,204.
Since last month, XFOR stock retreated -13.93%. Shares of the company fell to $1.0000 on 09/21/23, the lowest level in the past month. A 52-week high of $2.58 was reached on 06/13/23 after having rallying from a 52-week low of $0.65. Since the beginning of this year, XFOR’s stock price has risen by 5.74% or $0.0570, and marked a new high 23 times. However, the stock has declined by -59.22% since its 52-week high.
XFOR stock investors should be aware that X4 Pharmaceuticals Inc. (XFOR) stock had its last reported insider trading activity 14 days ago on Sep 08. DiBiase Mary, the Chief Operating Officer of the company, disposed of 2,642 shares for $1.25 on Sep 08. It resulted in a $3,300 divestment by the insider. WYZGA MICHAEL S added 25,000 shares at an average price of $1.20 on Aug 18. The insider now owns 76,667 shares following the transaction. On Aug 10, Interim Chief Medical Officer Stewart Murray sold 130,056 shares at $1.06 apiece. The transaction was valued at $137,859.
Financial Health
In the three months ended June 29, X4 Pharmaceuticals Inc.’s quick ratio stood at 6.60, while its current ratio was 6.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.47, and the total debt-to-equity ratio was 0.48. Based on annual data, XFOR earned $87.57 million in gross profit.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected X4 Pharmaceuticals Inc. to report -$0.16 quarterly earnings, the actual figure was -$0.33 per share, beating the consensus estimate by -106.20%. During the quarter, the company generated -$25.68 million in EBITDA. The liabilities of X4 Pharmaceuticals Inc. were 105.86 million at the end of its most recent quarter ended June 29, and its total debt was $36.87 million. The value of shareholders’ equity is $164.43 million.
Technical Picture
This quick technical analysis looks at X4 Pharmaceuticals Inc.’s (XFOR) price momentum. With a historical volatility rate of 55.13%, the RSI 9-day stood at 27.13% on 21 September.
With respect to its five-day moving average, the current X4 Pharmaceuticals Inc. price is down by -13.22% percent or -$0.1600. At present, XFOR shares trade -17.97% below its 20-day simple moving average and -28.57% percent below its 100-day simple moving average. However, the stock is currently trading approximately -44.74% below its SMA50 and -23.91% below its SMA200.
Stochastic coefficient K was 10.69% and Stochastic coefficient D was 11.32%, while ATR was 0.0874. Given the Stochastic reading of 15.15% for the 14-day period, the RSI (14) reading has been calculated as 31.46%. As of today, the MACD Oscillator reading stands at -0.0767, while the 14-day reading stands at -0.1265.
Analyst Ratings
X4 Pharmaceuticals Inc. (XFOR) has been rated Buy by analysts. According to 0 brokerage firms, XFOR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate X4 Pharmaceuticals Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $3.00, the current consensus forecast for the stock is $2.60 – $5.00. Based on these forecasts, analysts predict X4 Pharmaceuticals Inc. (XFOR) will achieve an average price target of $3.51.
